Researchers at Karolinska Institute have developed a novel method using DNA Nanoballs to detect pathogens, aiming to simplify nucleic acid testing and revolutionize pathogen detection.
FASEB’s Excellence in Science Awards highlight outstanding achievements by women in the biological and biomedical sciences. The awards are bestowed to female scientists demonstrating not only excellence and innovation in their research fields, but exemplary leadership and mentorship as well.
The blood-brain barrier (BBB) has been found to play a significant role in controlling behavior critical to how ant colonies function, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs.
Scientists at St. Jude Children’s Research Hospital found that a subset of CD8+ T cells in the brain lessens the activation of microglia and limits disease pathology in a model of Alzheimer’s disease.
A research team, affiliated with UNIST has achieved a groundbreaking milestone in tissue regeneration by developing a technology that utilizes autologous blood to produce three-dimensional microvascular implants.
September is National Sickle Cell Awareness Month. Johns Hopkins Medicine experts who specialize in sickle cell disease are available to speak with reporters about health equity issues related to sickle cell disease.
Beckman researchers and collaborators received $30 million from the U.S. National Science Foundation to establish the NSF Science and Technology Center for Quantitative Cell Biology.
Russian neurobiologists have created computer software that can automatically analyze and classify the shape of dendritic spines. The program is based on machine learning techniques.
Van Andel Institute scientists and collaborators have identified a key part of a mechanism that annotates genetic information before it is passed from fathers to their offspring.
A newly discovered way of optimising plant enzymes through bioengineering has increased knowledge of how plant material can be converted into biofuels, biochemicals and other high-value products.
Researchers have determined how Leishmaniasis vaccine candidates, created using mutated disease-causing parasites, prompt molecular-level changes in host cells that have specific roles in helping generate the immune response.
A group of researchers has unearthed the secrets behind a tiny but crucial protein that shuttles zinc ions (Zn2+) within our bodies. The discovery offers a deeper understanding of how our cells maintain optimal health.
Our cells are powered by tiny “powerplants” called mitochondria, which transform nutrients into fuel that sustains life. But there’s more to the story of mitochondria, says Van Andel Institute Assistant Professor Sara Nowinski, Ph.D.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include a novel computational tool to detect single base pair DNA changes in single-cell sequencing data, a potential target to treat hypertension caused by drugs commonly used in organ transplants, further insights into the steps involved in genetic recombination, a novel treatment target for a subset of adenoid cystic carcinoma (ACC), a combination therapy that improves outcomes in certain patients with acute myeloid leukemia (AML), and a target for treating prolonged cytopenia in patients with relapsed/refractory large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapy.
Olgica Milenkovic’s group has been developing machine learning approaches that can tell revealing new stories about biological phenomena—but her work has very old roots.
In Journal of Applied Physics, Markus Buehler combines attention neural networks with graph neural networks to better understand and design proteins. The approach couples the strengths of geometric deep learning with those of language models to predict existing protein properties and envision new proteins that nature has not yet devised. Buehler’s model turns numbers, descriptions, tasks, and other elements into symbols for his neural networks to use.
Dr. Yoon Ki Joung and Dr. Juro Lee of the Biomaterials Research Center at the Korea Institute of Science and Technology (KIST), together with Prof. Hun-Jun Park and Dr. Bong-Woo Park of the Catholic University of Korea College of Medicine, have developed a new treatment for myocardial infarction that uses nanovesicles derived from fibroblasts with induced apoptosis to modulate the immune response.
Short-lived proteins control gene expression in cells to carry out a number of vital tasks, from helping the brain form connections to helping the body mount an immune defense. These proteins are made in the nucleus and are quickly destroyed once they’ve done their job.
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.
Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio.
As a single organ, our skin is able to perform a broad repertoire of vital functions. Dermatology experts call for a reference guide to single-cell composition of normal human skin, which is still lacking.
The discovery that birds evolved from small carnivorous dinosaurs of the Late Jurassic was made possible by recently discovered fossils of theropods such as Tyrannosaurus rex and the smaller velociraptors. In a way, you could say that dinosaurs are still with us and seen tweeting from your own backyard! Below are the latest research headlines in the Birds channel on Newswise.
According to new research in the journal Immunity, T cells have a nuclear receptor doing something very odd—but very important—to help them fight pathogens and destroy cancer cells.
A new study highlights the potential of artificial DNA structures that, when fitted with antibodies, instruct the immune system to specifically target cancerous cells.
The August 2023 issue of SLAS Technology, the open access journal emphasizing scientific and technical advances across the life sciences, is now available.
New animal research suggests that little-studied brain cells known as astrocytes are major players in controlling sleep need and may someday help humans go without sleep for longer without negative consequences such as mental fatigue and impaired physical health.
St. Jude Children’s Research Hospital scientists found that immune cells present in individuals long before influenza infection predict whether the illness is symptomatic.
Todd Aguilera, M.D., Ph.D., Assistant Professor of Radiation Oncology and member of the Experimental Therapeutics Program in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, has been named one of 11 inaugural Cancer Moonshot Scholars. The national program recognizes a cohort of early-career investigators from underrepresented groups who have been identified as emerging leaders in cancer research and innovation.
Joann B. Sweasy, PhD, has been elected to serve as vice president/president-elect of AACI’s Board of Directors. Three new board members were also chosen: Edward Chu, MD, MMS; Raymond N. DuBois, MD, PhD; and Yolanda Sanchez, PhD.
Two molecular languages at the origin of life have been successfully recreated and mathematically validated, thanks to pioneering work by Canadian scientists at Université de Montréal.
Bioengineers can tailor the genomes of cells to create “cellular therapies” that fight disease, but they have found it difficult to design specialized activating proteins called transcription factors that can throw the switch on bioengineered genes without occasionally turning on some of the cell’s naturally occurring genes.
Nanovesicles can be bioengineered to target cancer cells and deliver treatments directly, according to research at Binghamton University, State University of New York.
Researchers at UT Southwestern Medical Center have identified a novel parameter of T cells that could help oncologists anticipate which patients would be most likely to develop immunotherapy toxicity. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to improved treatments for a variety of cancers.
Patients with the genetic disorder hemophilia A receive factor VIII protein replacement treatments to replenish this clotting protein in their blood, thus preventing dangerous bleeding. Unfortunately, about 30 percent of these patients develop antibodies against the treatment and until now, despite more than 80 years of clinical experience with this complication, little has been known about its mechanism.
Researchers at Oak Ridge National Laboratory used neutrons and x-rays to draw a roadmap of every atom, chemical bond and electrical charge inside a key metabolic pathway in the body that cancer cells hijack and dramatically overuse to reproduce. The study essentially paves the way for developing new drugs that act as roadblocks that cut off the supply of vital resources to cancer cells. The drugs would be designed to target highly aggressive tumor-forming cancers that too often become terminal such as lung, colon, breast, pancreatic and prostate cancers.
A new study from clinicians and researchers at the University of Michigan Rogel Cancer Center, U-M Department of Pathology and the Michigan Center for Translational Pathology reveals findings from over 800 clinical assays performed for kidney patients with MiTF family gene mutations.